Merck delivered Q4 2025 revenue growth driven by strong KEYTRUDA and WINREVAIR performance, while GAAP earnings declined year over year due to higher restructuring and acquisition-related costs.

Merck delivered strong Q3 2025 results with increased revenue and EPS, fueled by continued demand for KEYTRUDA and WINREVAIR, despite a notable decline in GARDASIL sales.

Merck posted Q2 2025 results showing a modest decline in revenue and net income, with strong sales of KEYTRUDA partially offset by a steep drop in GARDASIL sales. The company highlighted a cost-saving initiative and a strategic acquisition to bolster future growth.

Merck saw revenue dip slightly to $15.5B in Q1 2025, with earnings per share increasing on both a GAAP and non-GAAP basis. Strength in oncology, particularly KEYTRUDA, and growth in animal health helped offset vaccine declines, especially GARDASIL sales in China.

Merck reported a 7% increase in fourth-quarter 2024 sales, reaching $15.6 billion, driven by strong performance in oncology and animal health segments. However, challenges in the vaccine segment, particularly with Gardasil in China, impacted overall results.

Merck reported a 4% increase in worldwide sales, reaching $16.7 billion in Q3 2024. GAAP EPS was $1.24, and non-GAAP EPS was $1.57. The results were driven by KEYTRUDA, new product launches like WINREVAIR, and strong growth in Animal Health, offset by declines in other products.

Merck reported strong Q2 2024 results, with GAAP EPS at $2.14 and non-GAAP EPS at $2.28. The company highlighted the launch of WINREVAIR and progress in its pipeline.

Merck reported a strong start to 2024, driven by innovation and a broad commercial portfolio. Key therapeutic areas experienced significant growth, and the company launched WINREVAIR in the U.S. The company is raising and narrowing its full-year outlook ranges for sales and non-GAAP EPS.

Merck's fourth-quarter earnings were impacted by a $5.5 billion charge related to a collaboration with Daiichi Sankyo, leading to a GAAP loss per share of $0.48 and non-GAAP EPS of $0.03. Full-year pharmaceutical sales grew, driven by oncology, vaccines and hospital acute care products, offset by lower sales of LAGEVRIO and JANUVIA/JANUMET.

Merck announced its third-quarter 2023 financial results, with GAAP EPS at $1.86 and non-GAAP EPS at $2.13. The increases in EPS were primarily due to operational strength, and were partially offset by the unfavorable impact of foreign exchange.

Merck announced its second-quarter 2023 financial results, revealing robust underlying growth despite a GAAP loss per share of $2.35 and a non-GAAP loss per share of $2.06. These losses were primarily due to a charge for the acquisition of Prometheus Biosciences, Inc. and were further affected by lower sales of LAGEVRIO and unfavorable foreign exchange impacts.

Merck's first-quarter 2023 sales were $12.7 billion, a 10% decrease compared to the first quarter of 2022. GAAP EPS was $1.11 and non-GAAP EPS was $1.40.

Merck reported a 1% increase in fourth-quarter pharmaceutical sales, reaching $12.2 billion, driven by oncology and hospital acute care, while animal health sales saw a 2% decline. GAAP EPS was $1.18, and non-GAAP EPS was $1.62. The company anticipates full-year 2023 revenue between $57.2 billion and $58.7 billion.

Merck reported strong Q3 2022 results, with revenue increasing by 13% to $13.0 billion in Pharmaceutical sales and Non-GAAP EPS of $1.85. The growth was primarily driven by Keytruda and Gardasil sales.

Merck announced strong second-quarter 2022 financial results, with pharmaceutical sales increasing by 28% to $12.8 billion. Key drivers included oncology (particularly KEYTRUDA), vaccines (GARDASIL/GARDASIL 9), and hospital acute care products. The company is raising and narrowing its full-year guidance for sales.

Merck reported strong first-quarter results, driven by clinical advancements and commercial execution. Total sales increased, led by oncology, vaccines, and hospital acute care products, with significant contributions from KEYTRUDA and GARDASIL. The company is raising and narrowing its full-year guidance for revenues and EPS.

Merck reported strong fourth-quarter and full-year 2021 financial results, driven by growth in oncology, vaccines, and hospital acute care products, as well as the introduction of molnupiravir. The company achieved significant progress against its strategic priorities, including advancing its pipeline and closing the acquisition of Acceleron Pharma Inc.

Merck announced strong Q3 2021 financial results, driven by key products like KEYTRUDA and GARDASIL. The company is also advancing its pipeline with positive Phase 3 results for molnupiravir and the planned acquisition of Acceleron.

Merck reported a strong second quarter in 2021, with pharmaceutical sales increasing by 22% to $10.0 billion and animal health sales totaling $1.5 billion, up 34% year-over-year. GAAP EPS was $0.48, which includes a $1.7 billion charge for the acquisition of Pandion Therapeutics, Inc, and non-GAAP EPS was $1.31.

Merck's first-quarter 2021 results were impacted by the COVID-19 pandemic, with pharmaceutical sales of $10.7 billion. Despite these challenges, Keytruda sales rose 19% to $3.9 billion, and Animal Health sales increased by 17% to $1.4 billion. The company's GAAP EPS was $1.25, and non-GAAP EPS was $1.40.

Merck's Q4 2020 results showed an 8% increase in pharmaceutical sales, driven by oncology and vaccine growth, despite a $400 million negative impact from COVID-19. GAAP EPS was $(0.83), including charges for acquisitions and impairments, while non-GAAP EPS was $1.32. The company anticipates full-year 2021 revenue to be between $51.8 billion and $53.8 billion.

Merck reported solid third-quarter results, driven by growth in oncology and animal health, despite the negative impact of the COVID-19 pandemic. Keytruda sales grew significantly, contributing to the overall revenue increase. The company is confident in achieving solid full-year revenue growth and advancing its pipeline.

Merck's second-quarter 2020 earnings were affected by the COVID-19 pandemic, with a negative impact on revenue, particularly in pharmaceuticals and animal health. Despite these challenges, the company saw improved business momentum throughout the quarter and remains confident in its long-term growth prospects, driven by its portfolio of medicines, vaccines, and animal health products. Merck is also actively involved in developing vaccines and antivirals to combat the SARS-CoV-2 pandemic.

Merck's Q1 2020 showed a strong performance driven by oncology and vaccines, with revenue increasing by 10% to $10.7 billion. GAAP EPS was $1.26, and non-GAAP EPS was $1.50. The company anticipates an unfavorable impact to revenue of approximately $2.1 billion for the full year due to COVID-19.

Merck's Q4 2019 results showed strong growth in pharmaceutical sales, driven by oncology, particularly KEYTRUDA, and animal health, boosted by the Antelliq acquisition. The company's GAAP EPS was $0.92, and non-GAAP EPS was $1.16. Merck also announced its plan to spin off its Women’s Health, trusted Legacy Brands, and Biosimilar products into a new company.